New pill shows promise for controlling painful skin condition in long-term trial
NCT ID NCT07665437
First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This phase 3 study tests the long-term safety and effectiveness of remibrutinib, an oral drug, in 710 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants have already completed a prior remibrutinib study. The trial compares two doses and tracks side effects and reduction in skin lesions over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remibrutinib (oral drug)
- What this could lead to
- If successful, this could provide a new long-term treatment option to control painful skin abscesses and inflammation in hidradenitis suppurativa.
- What could go wrong
- This is an extension study, so participants already tolerated the drug, but long-term safety and effectiveness are still being confirmed. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGCaba, Buenos Aires, C1119ACN, Argentina
-
Novartis Investigative Site
RECRUITINGCABA, C1428DZF, Argentina
-
Novartis Investigative Site
RECRUITINGSydney, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could childhood trauma fuel skin inflammation?
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New shot could ease painful skin condition
- New pill for painful skin disease enters first human tests